Oric Pharmaceuticals
ORIC
82 hedge funds and large institutions have $762M invested in Oric Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 6 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 20
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
19% more capital invested
Capital invested by funds: $639M → $762M (+$123M)
5% more funds holding
Funds holding: 78 → 82 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5.86% less ownership
Funds ownership: 98.49% → 92.63% (-5.9%)
Top Buyers
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$10.3M |
| 3 |
EC
Euclidean Capital
New York
|
-$4.45M |
| 4 |
Millennium Management
New York
|
-$4.1M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.89M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
76
Penserra Capital Management
Orinda,
California
| $18K | +$1.32K | +65 | +8% |
|
77
Daiwa Securities Group
Tokyo,
Japan
| $3K | +$1.34K | +66 | +96% |
|
78
Simplex Trading
Chicago,
Illinois
| $2K | – | – | – |
|
|
S
79
SignatureFD
Atlanta,
Georgia
| $2K | +$1.62K | +80 | New |
|
|
BCA
80
Berman Capital Advisors
Atlanta,
Georgia
| $2K | +$2.29K | +113 | New |
|
81
Nisa Investment Advisors
St. Louis,
Missouri
| $70 | – | – | – |
|
|
RCM
82
RA Capital Management
Boston,
Massachusetts
| – | -$10.3M | -584,000 | Closed |
|
|
83
Millennium Management
New York
| – | -$4.1M | -231,853 | Closed |
|
84
Two Sigma Investments
New York
| – | -$542K | -30,641 | Closed |
|
85
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$398K | -22,512 | Closed |
|
|
PHK
86
Point72 Hong Kong
Hong Kong
| – | -$34K | -1,895 | Closed |
|
|
OSAM
87
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$27K | -1,544 | Closed |
|
|
PA
88
Parallel Advisors
San Francisco,
California
| – | +$41 | +2 | New |
|
ORIC Hedge Fund Activity: Q3 2021 in Review
82 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q3 2021, worth a combined $762M — up 19% from $639M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ORIC positions and 6 closed out — a net gain of 4 holders — while 34 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $7.97M. The largest seller was Point72 Asset Management, cutting an estimated $12.4M.
- 82 institutional investors held Oric Pharmaceuticals (ORIC) as of Q3 2021, up from 78 in Q2 2021.
- Funds reported $762M of Oric Pharmaceuticals stock for Q3 2021, up 19% quarter-over-quarter.
- 10 funds opened new Oric Pharmaceuticals positions in Q3 2021 and 6 closed out, a net change of +4 holders.
- The largest Oric Pharmaceuticals buyer in Q3 2021 was Fidelity Investments, an estimated $7.97M added.
- The largest Oric Pharmaceuticals seller in Q3 2021 was Point72 Asset Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q3 2021.